TruSpine Technolgs. - Director/PDMR Shareholding
Announcement provided by
TruSpine Technologies Plc · TSP18/03/2024 07:00
18 March 2024
TruSpine Technologies plc
("TruSpine" or the "Company")
Director Dealing
TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that it received notification on 15 March 2024 that Geoff Miller, Chairman of the Company, made the following purchase of ordinary shares in the capital of the Company on 15 March 2024. Further details are set out in the Notification of Dealing Form below.
|
Director |
Purchase price (Aggregated) |
Ordinary shares purchased |
Resultant interest in ordinary shares |
Resultant percentage of issued ordinary shares |
|
Geoff Miller |
|
250,000 |
2,050,000 |
1.70% |
This announcement contains inside information for the purposes of the
Enquiries:
|
TruSpine Technologies Plc |
Tel: +44 (0)20 7118 0852 |
|
Laurence Strauss, Chief Executive Officer |
|
|
|
|
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser) |
Tel: +44 (0)20 7213 0880 |
|
Liam Murray / Ludovico Lazzaretti |
|
|
Peterhouse Capital Limited (Broker & Financial Adviser) |
|
|
Lucy Williams / Duncan Vasey
|
|
|
Novus Communications (PR and IR) |
Tel: +44 (0)207 448 9839 |
|
Alan Green / Jacqueline Briscoe |
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
Geoffrey Richard Miller |
|||||
|
2 |
Reason for notification |
|
|||||
|
a. |
Position/Status |
Chairman
|
|||||
|
b. |
Initial notification/ Amendment |
Initial notification |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
TruSpine Technologies Plc |
|||||
|
b. |
LEI |
213800HNZX9B1QZPB225 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of
ISIN: GB00BMZCKL55 |
|||||
|
b. |
Nature of the transaction |
Purchase of ordinary shares
|
|||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
||||
|
|
250,000 |
|
|||||
|
|
|||||||
|
d. |
Aggregated information - Volume - Price |
N/A |
|||||
|
e. |
Date of the transaction |
15 March 2024 |
|||||
|
f. |
Place of the transaction |
Aquis Stock Exchange |
|||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.